Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN ...Middle East

Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN If approved, Aspaveli (pegcetacoplan) would be the first C3G and primary IC-MPGN treatment for patients 12 and older STOCKHOLM, Dec. 12, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the Committee...

Hence then, the article about sobi receives positive chmp opinion for aspaveli pegcetacoplan for the treatment of c3g and primary ic mpgn was published today ( Friday 12/12/2025 - 04:18 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN )

Also on site :

• My Big Family Once Formed the Backbone of My Life. Then, We Discovered My Sister’s Horrific Actions. Now Nothing Is the Same.
• ‘Fire Country’ Announces Major Change After Season 4 Cast Shake-Up
• ‘Beloved’ Woodford Reserve Bourbon Is Back Nationwide